Global Small Molecule Targeted Cancer Therapy
Global Small Molecule Targeted Cancer Therapy

Small Molecule Targeted Cancer Therapy Comprehensive Study by Type (Monoclonal Antibodies, Small Molecules, Small Molecule Drug Conjugates), Application (Lymphoma, Melanoma, Multiple Myeloma, Breast Cancer, Prostate Cancer, Other Cancers), Target Molecule (Tyrosine & Serine/Threonine Kinases, Proteosomes, MMPs and HSPs, Apoptosis), End Use (Hospitals, Specialty Surgical Centers) Players and Region - Global Market Outlook to 2026

Small Molecule Targeted Cancer Therapy Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 214 Pages 200 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Market Snapshot:
The creation of new antitumor therapeutics, especially new chemotherapy and targeted therapy, is a perennial subject that keeps up with the times. Owing to its high morbidity and longevity, cancer is the second major cause of death. Cytotoxic medications have had a lot of effectiveness in treating tumors, but their cytotoxic effects can also damage healthy cells in the body, causing severe side effects. Targeted treatment varies from conventional chemotherapy in that it inhibits certain genes or proteins that distinguish cancer cells from normal cells. These genes or proteins are often involved in cancer development, proliferation, and metastasis. Cancers such as lung, colorectal, breast, lymphoma, and leukaemia benefit from selective cancer treatments because they work on subtle molecular modifications that are special to each cancer. As a result, Small Molecule targeted therapy offers a more precise treatment choice, with patients receiving medications that target particular molecular targets linked to cancer.

Market Drivers
  • Higher Response Rate
  • Prevalence of Chronic Cancer Cases

Market Trend
  • Rising Healthcare Infrastructure
  • Expensive Procedures

Restraints
  • Side Effects Such as Hair Loss & Fatigue
  • Lack of Trained Professionals


The key Players profiled in the report are Abbott Laboratories (United States), GlaxoSmithKline plc (United Kingdom), Pfizer Inc. (United States), Mylan Pharmaceuticals (United States), OncoGenex Pharmaceuticals (United States), Cytokinetics Inc. (United States), Hospira Inc. (United States), Boehringer Ingelheim GmbH (Germany) and Bayer HealthCare AG (Germany).

Report Objectives / Segmentation Covered
By Type
  • Monoclonal Antibodies
  • Small Molecules
  • Small Molecule Drug Conjugates
By Application
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Breast Cancer
  • Prostate Cancer
  • Other Cancers
By Target Molecule
  • Tyrosine & Serine/Threonine Kinases
  • Proteosomes
  • MMPs and HSPs
  • Apoptosis

By End Use
  • Hospitals
  • Specialty Surgical Centers

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Higher Response Rate
      • 3.2.2. Prevalence of Chronic Cancer Cases
    • 3.3. Market Challenges
      • 3.3.1. Changes of Blood Clotting
    • 3.4. Market Trends
      • 3.4.1. Rising Healthcare Infrastructure
      • 3.4.2. Expensive Procedures
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Small Molecule Targeted Cancer Therapy, by Type, Application, Target Molecule, End Use and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Small Molecule Targeted Cancer Therapy (Value)
      • 5.2.1. Global Small Molecule Targeted Cancer Therapy by: Type (Value)
        • 5.2.1.1. Monoclonal Antibodies
        • 5.2.1.2. Small Molecules
        • 5.2.1.3. Small Molecule Drug Conjugates
      • 5.2.2. Global Small Molecule Targeted Cancer Therapy by: Application (Value)
        • 5.2.2.1. Lymphoma
        • 5.2.2.2. Melanoma
        • 5.2.2.3. Multiple Myeloma
        • 5.2.2.4. Breast Cancer
        • 5.2.2.5. Prostate Cancer
        • 5.2.2.6. Other Cancers
      • 5.2.3. Global Small Molecule Targeted Cancer Therapy by: Target Molecule (Value)
        • 5.2.3.1. Tyrosine & Serine/Threonine Kinases
        • 5.2.3.2. Proteosomes
        • 5.2.3.3. MMPs and HSPs
        • 5.2.3.4. Apoptosis
      • 5.2.4. Global Small Molecule Targeted Cancer Therapy by: End Use (Value)
        • 5.2.4.1. Hospitals
        • 5.2.4.2. Specialty Surgical Centers
      • 5.2.5. Global Small Molecule Targeted Cancer Therapy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Small Molecule Targeted Cancer Therapy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline plc (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Pfizer Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. OncoGenex Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Cytokinetics Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Hospira Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim GmbH (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer HealthCare AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Small Molecule Targeted Cancer Therapy Sale, by Type, Application, Target Molecule, End Use and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Small Molecule Targeted Cancer Therapy (Value)
      • 7.2.1. Global Small Molecule Targeted Cancer Therapy by: Type (Value)
        • 7.2.1.1. Monoclonal Antibodies
        • 7.2.1.2. Small Molecules
        • 7.2.1.3. Small Molecule Drug Conjugates
      • 7.2.2. Global Small Molecule Targeted Cancer Therapy by: Application (Value)
        • 7.2.2.1. Lymphoma
        • 7.2.2.2. Melanoma
        • 7.2.2.3. Multiple Myeloma
        • 7.2.2.4. Breast Cancer
        • 7.2.2.5. Prostate Cancer
        • 7.2.2.6. Other Cancers
      • 7.2.3. Global Small Molecule Targeted Cancer Therapy by: Target Molecule (Value)
        • 7.2.3.1. Tyrosine & Serine/Threonine Kinases
        • 7.2.3.2. Proteosomes
        • 7.2.3.3. MMPs and HSPs
        • 7.2.3.4. Apoptosis
      • 7.2.4. Global Small Molecule Targeted Cancer Therapy by: End Use (Value)
        • 7.2.4.1. Hospitals
        • 7.2.4.2. Specialty Surgical Centers
      • 7.2.5. Global Small Molecule Targeted Cancer Therapy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Small Molecule Targeted Cancer Therapy: by Type(USD Million)
  • Table 2. Small Molecule Targeted Cancer Therapy Monoclonal Antibodies , by Region USD Million (2015-2020)
  • Table 3. Small Molecule Targeted Cancer Therapy Small Molecules , by Region USD Million (2015-2020)
  • Table 4. Small Molecule Targeted Cancer Therapy Small Molecule Drug Conjugates , by Region USD Million (2015-2020)
  • Table 5. Small Molecule Targeted Cancer Therapy: by Application(USD Million)
  • Table 6. Small Molecule Targeted Cancer Therapy Lymphoma , by Region USD Million (2015-2020)
  • Table 7. Small Molecule Targeted Cancer Therapy Melanoma , by Region USD Million (2015-2020)
  • Table 8. Small Molecule Targeted Cancer Therapy Multiple Myeloma , by Region USD Million (2015-2020)
  • Table 9. Small Molecule Targeted Cancer Therapy Breast Cancer , by Region USD Million (2015-2020)
  • Table 10. Small Molecule Targeted Cancer Therapy Prostate Cancer , by Region USD Million (2015-2020)
  • Table 11. Small Molecule Targeted Cancer Therapy Other Cancers , by Region USD Million (2015-2020)
  • Table 12. Small Molecule Targeted Cancer Therapy: by Target Molecule(USD Million)
  • Table 13. Small Molecule Targeted Cancer Therapy Tyrosine & Serine/Threonine Kinases , by Region USD Million (2015-2020)
  • Table 14. Small Molecule Targeted Cancer Therapy Proteosomes , by Region USD Million (2015-2020)
  • Table 15. Small Molecule Targeted Cancer Therapy MMPs and HSPs , by Region USD Million (2015-2020)
  • Table 16. Small Molecule Targeted Cancer Therapy Apoptosis , by Region USD Million (2015-2020)
  • Table 17. Small Molecule Targeted Cancer Therapy: by End Use(USD Million)
  • Table 18. Small Molecule Targeted Cancer Therapy Hospitals , by Region USD Million (2015-2020)
  • Table 19. Small Molecule Targeted Cancer Therapy Specialty Surgical Centers , by Region USD Million (2015-2020)
  • Table 20. South America Small Molecule Targeted Cancer Therapy, by Country USD Million (2015-2020)
  • Table 21. South America Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 22. South America Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 23. South America Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 24. South America Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 25. Brazil Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 26. Brazil Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 27. Brazil Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 28. Brazil Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 29. Argentina Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 30. Argentina Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 31. Argentina Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 32. Argentina Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 33. Rest of South America Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 34. Rest of South America Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 35. Rest of South America Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 36. Rest of South America Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 37. Asia Pacific Small Molecule Targeted Cancer Therapy, by Country USD Million (2015-2020)
  • Table 38. Asia Pacific Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 39. Asia Pacific Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 40. Asia Pacific Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 41. Asia Pacific Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 42. China Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 43. China Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 44. China Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 45. China Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 46. Japan Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 47. Japan Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 48. Japan Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 49. Japan Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 50. India Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 51. India Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 52. India Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 53. India Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 54. South Korea Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 55. South Korea Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 56. South Korea Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 57. South Korea Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 58. Taiwan Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 59. Taiwan Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 60. Taiwan Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 61. Taiwan Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 62. Australia Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 63. Australia Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 64. Australia Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 65. Australia Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 66. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 67. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 70. Europe Small Molecule Targeted Cancer Therapy, by Country USD Million (2015-2020)
  • Table 71. Europe Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 72. Europe Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 73. Europe Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 74. Europe Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 75. Germany Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 76. Germany Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 77. Germany Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 78. Germany Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 79. France Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 80. France Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 81. France Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 82. France Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 83. Italy Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 84. Italy Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 85. Italy Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 86. Italy Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 87. United Kingdom Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 88. United Kingdom Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 89. United Kingdom Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 90. United Kingdom Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 91. Netherlands Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 92. Netherlands Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 93. Netherlands Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 94. Netherlands Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 95. Rest of Europe Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 96. Rest of Europe Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 97. Rest of Europe Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 98. Rest of Europe Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 99. MEA Small Molecule Targeted Cancer Therapy, by Country USD Million (2015-2020)
  • Table 100. MEA Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 101. MEA Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 102. MEA Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 103. MEA Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 104. Middle East Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 105. Middle East Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 106. Middle East Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 107. Middle East Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 108. Africa Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 109. Africa Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 110. Africa Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 111. Africa Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 112. North America Small Molecule Targeted Cancer Therapy, by Country USD Million (2015-2020)
  • Table 113. North America Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 114. North America Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 115. North America Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 116. North America Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 117. United States Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 118. United States Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 119. United States Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 120. United States Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 121. Canada Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 122. Canada Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 123. Canada Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 124. Canada Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 125. Mexico Small Molecule Targeted Cancer Therapy, by Type USD Million (2015-2020)
  • Table 126. Mexico Small Molecule Targeted Cancer Therapy, by Application USD Million (2015-2020)
  • Table 127. Mexico Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2015-2020)
  • Table 128. Mexico Small Molecule Targeted Cancer Therapy, by End Use USD Million (2015-2020)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Small Molecule Targeted Cancer Therapy: by Type(USD Million)
  • Table 139. Small Molecule Targeted Cancer Therapy Monoclonal Antibodies , by Region USD Million (2021-2026)
  • Table 140. Small Molecule Targeted Cancer Therapy Small Molecules , by Region USD Million (2021-2026)
  • Table 141. Small Molecule Targeted Cancer Therapy Small Molecule Drug Conjugates , by Region USD Million (2021-2026)
  • Table 142. Small Molecule Targeted Cancer Therapy: by Application(USD Million)
  • Table 143. Small Molecule Targeted Cancer Therapy Lymphoma , by Region USD Million (2021-2026)
  • Table 144. Small Molecule Targeted Cancer Therapy Melanoma , by Region USD Million (2021-2026)
  • Table 145. Small Molecule Targeted Cancer Therapy Multiple Myeloma , by Region USD Million (2021-2026)
  • Table 146. Small Molecule Targeted Cancer Therapy Breast Cancer , by Region USD Million (2021-2026)
  • Table 147. Small Molecule Targeted Cancer Therapy Prostate Cancer , by Region USD Million (2021-2026)
  • Table 148. Small Molecule Targeted Cancer Therapy Other Cancers , by Region USD Million (2021-2026)
  • Table 149. Small Molecule Targeted Cancer Therapy: by Target Molecule(USD Million)
  • Table 150. Small Molecule Targeted Cancer Therapy Tyrosine & Serine/Threonine Kinases , by Region USD Million (2021-2026)
  • Table 151. Small Molecule Targeted Cancer Therapy Proteosomes , by Region USD Million (2021-2026)
  • Table 152. Small Molecule Targeted Cancer Therapy MMPs and HSPs , by Region USD Million (2021-2026)
  • Table 153. Small Molecule Targeted Cancer Therapy Apoptosis , by Region USD Million (2021-2026)
  • Table 154. Small Molecule Targeted Cancer Therapy: by End Use(USD Million)
  • Table 155. Small Molecule Targeted Cancer Therapy Hospitals , by Region USD Million (2021-2026)
  • Table 156. Small Molecule Targeted Cancer Therapy Specialty Surgical Centers , by Region USD Million (2021-2026)
  • Table 157. South America Small Molecule Targeted Cancer Therapy, by Country USD Million (2021-2026)
  • Table 158. South America Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 159. South America Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 160. South America Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 161. South America Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 162. Brazil Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 163. Brazil Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 164. Brazil Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 165. Brazil Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 166. Argentina Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 167. Argentina Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 168. Argentina Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 169. Argentina Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 170. Rest of South America Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 171. Rest of South America Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 172. Rest of South America Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 173. Rest of South America Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 174. Asia Pacific Small Molecule Targeted Cancer Therapy, by Country USD Million (2021-2026)
  • Table 175. Asia Pacific Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 176. Asia Pacific Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 177. Asia Pacific Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 178. Asia Pacific Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 179. China Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 180. China Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 181. China Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 182. China Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 183. Japan Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 184. Japan Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 185. Japan Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 186. Japan Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 187. India Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 188. India Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 189. India Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 190. India Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 191. South Korea Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 192. South Korea Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 193. South Korea Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 194. South Korea Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 195. Taiwan Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 196. Taiwan Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 197. Taiwan Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 198. Taiwan Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 199. Australia Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 200. Australia Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 201. Australia Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 202. Australia Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 203. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 204. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 205. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 206. Rest of Asia-Pacific Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 207. Europe Small Molecule Targeted Cancer Therapy, by Country USD Million (2021-2026)
  • Table 208. Europe Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 209. Europe Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 210. Europe Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 211. Europe Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 212. Germany Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 213. Germany Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 214. Germany Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 215. Germany Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 216. France Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 217. France Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 218. France Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 219. France Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 220. Italy Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 221. Italy Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 222. Italy Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 223. Italy Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 224. United Kingdom Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 225. United Kingdom Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 226. United Kingdom Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 227. United Kingdom Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 228. Netherlands Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 229. Netherlands Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 230. Netherlands Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 231. Netherlands Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 232. Rest of Europe Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 233. Rest of Europe Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 234. Rest of Europe Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 235. Rest of Europe Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 236. MEA Small Molecule Targeted Cancer Therapy, by Country USD Million (2021-2026)
  • Table 237. MEA Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 238. MEA Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 239. MEA Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 240. MEA Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 241. Middle East Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 242. Middle East Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 243. Middle East Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 244. Middle East Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 245. Africa Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 246. Africa Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 247. Africa Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 248. Africa Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 249. North America Small Molecule Targeted Cancer Therapy, by Country USD Million (2021-2026)
  • Table 250. North America Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 251. North America Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 252. North America Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 253. North America Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 254. United States Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 255. United States Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 256. United States Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 257. United States Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 258. Canada Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 259. Canada Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 260. Canada Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 261. Canada Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 262. Mexico Small Molecule Targeted Cancer Therapy, by Type USD Million (2021-2026)
  • Table 263. Mexico Small Molecule Targeted Cancer Therapy, by Application USD Million (2021-2026)
  • Table 264. Mexico Small Molecule Targeted Cancer Therapy, by Target Molecule USD Million (2021-2026)
  • Table 265. Mexico Small Molecule Targeted Cancer Therapy, by End Use USD Million (2021-2026)
  • Table 266. Research Programs/Design for This Report
  • Table 267. Key Data Information from Secondary Sources
  • Table 268. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Small Molecule Targeted Cancer Therapy: by Type USD Million (2015-2020)
  • Figure 5. Global Small Molecule Targeted Cancer Therapy: by Application USD Million (2015-2020)
  • Figure 6. Global Small Molecule Targeted Cancer Therapy: by Target Molecule USD Million (2015-2020)
  • Figure 7. Global Small Molecule Targeted Cancer Therapy: by End Use USD Million (2015-2020)
  • Figure 8. South America Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 9. Asia Pacific Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 10. Europe Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 11. MEA Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 12. North America Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 13. Global Small Molecule Targeted Cancer Therapy share by Players 2020 (%)
  • Figure 14. Global Small Molecule Targeted Cancer Therapy share by Players (Top 3) 2020(%)
  • Figure 15. Global Small Molecule Targeted Cancer Therapy share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 18. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 19. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 21. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 23. Mylan Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Mylan Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 25. OncoGenex Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 26. OncoGenex Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 27. Cytokinetics Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Cytokinetics Inc. (United States) Revenue: by Geography 2020
  • Figure 29. Hospira Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Hospira Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Boehringer Ingelheim GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Boehringer Ingelheim GmbH (Germany) Revenue: by Geography 2020
  • Figure 33. Bayer HealthCare AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer HealthCare AG (Germany) Revenue: by Geography 2020
  • Figure 35. Global Small Molecule Targeted Cancer Therapy: by Type USD Million (2021-2026)
  • Figure 36. Global Small Molecule Targeted Cancer Therapy: by Application USD Million (2021-2026)
  • Figure 37. Global Small Molecule Targeted Cancer Therapy: by Target Molecule USD Million (2021-2026)
  • Figure 38. Global Small Molecule Targeted Cancer Therapy: by End Use USD Million (2021-2026)
  • Figure 39. South America Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 40. Asia Pacific Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 41. Europe Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 42. MEA Small Molecule Targeted Cancer Therapy Share (%), by Country
  • Figure 43. North America Small Molecule Targeted Cancer Therapy Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • GlaxoSmithKline plc (United Kingdom)
  • Pfizer Inc. (United States)
  • Mylan Pharmaceuticals (United States)
  • OncoGenex Pharmaceuticals (United States)
  • Cytokinetics Inc. (United States)
  • Hospira Inc. (United States)
  • Boehringer Ingelheim GmbH (Germany)
  • Bayer HealthCare AG (Germany)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation